An observational study in Hepatitis C, sponsored by Bristol-Myers Squibb. Completed at 2 sites in Mexico. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-18.
Sponsored by Bristol-Myers Squibb · Observational
This early post-marketing study is an observational, prospective and descriptive study of patients receiving daclatasvir for the treatment of Chronic Hepatitis C at participating sentinel sites for the CNFV in Mexico.
2,709 studies on the registry are indexed under Hepatitis A; 142 are open to participants now.
This study's planned enrollment of 10 is below the median of 250 across 687 observational studies indexed under Hepatitis A.
Browse Hepatitis A studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with chronic Hepatitis C who are being given daclatasvir for the treatment and cure of chronic Hepatitis C at the sentinel sites for the CNFV in Mexico. Patients will be treated according to the clinical judgment of the treating physician.
Exclusion Criteria:
patients receiving daclatasvir for the treatment of Chronic Hepatitis C at participating sentinel sites for the CNFV in Mexico
Other: Non-Interventional
Non-Interventional
Number of Adverse Events
adverse events (AEs) on treatment with DCV in patients with chronic hepatitis C treated by doctors at participating sentinel sites for the CNFV in Mexico
Time frame: Approximately 24 months
Distribution of Adverse Events by Age
Time frame: Approximately 24 months
Distribution of Adverse Events by Gender
Time frame: Approximately 24 months
Distribution of Adverse Events by Interruption or Switch of Medication
Time frame: Approximately 24 months
Distribution of Adverse Events by Concomitant Medication
Time frame: Approximately 24 months
Distribution of Adverse Events by Race
Time frame: Approximately 24 months
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb